Anergis SA
BiopĂ´le  III
Route de la Corniche 9B
CH-1066 Epalinges
Tel: +41- 21 651 92 20
Fax: +41 21 651 92 21
Email: info@anergis.ch

Welcome to Anergis

 

 

Anergis is a clinical-stage biopharmaceutical company based in Switzerland.

Anergis discovers and develops proprietary synthetic allergy vaccines with the aim to provide allergy patients and doctors with a significantly improved treatment option: ultra-fast desensitization.

Anergis COP allergy vaccines are pharmaceutical-grade products based on Contiguous Overlapping Peptides (COPs) and only need to be administered for 2 months in order to achieve long-lasting desensitization.

If you are interested to participate in one of our clinical trials, please send an email to info@anergis.ch

Upload company presentation

 

16 September 2014
Anergis Reports Positive Long-Term Clinical Efficacy of Lead Compound AllerT

03 June 2014
Anergis Appoints Dr. Vanya Beltrami as Director Product Development

27 May 2014
Anergis to Present New COP Allergy Vaccine Data at EAACI Conference 2014 in Copenhagen

23 April 2014
Anergis Completes Enrolment in the Long-Term Efficacy Trial of Lead Compound AllerT

27 February 2014
Phase IIb Results of Anergis´ Lead Compound AllerT to be Presented at 2014 AAAAI Annual Meeting in San Diego

05 February 2014
Anergis Closes Financing Round Totaling CHF 8 M

see details